Correlation between 5-α reductase and biological behavior of prostate cancer

doi:10.3969/j.issn.1006-7795.2016.03.010

Abstract

Abstract: Objective To investigate the correlation between the expression of two types of 5-αreductase and Gleason score, serum prostate-specific antigen (PSA) concentration, and TNM stage in prostate cancer (PCa). Methods Paraffin-embedded PCa specimens of 40 cases were collected in our hospital from 2013 to 2014. Other data of these patients were also collected including the basic information, prostate volume, preoperative serum PSA concentration, postoperative pathological TNM stage, Gleason score and so on. Chi-square test and Spearman rank correlation were used to analyze the correlation.Results The expression of type I 5-α reductase in PCa tissues was significantly stronger than that in the paraneoplastic tissues (Chi-square test, P <0.001). On the contrary, the expression of type II 5-α reductase in the paraneoplastic tissues was stronger than that in PCa tissues (Chi-square test, P=0.002). expression of type I 5-α reductase in PCa epithelial cells was positively correlated with patient's age, serum PSA, the degree of tumor malignancy, Gleason score, and clinical stage.Conclusion Expression of 5-α reductases in PCa are different, type I enzyme is increased, and type II enzyme is decreased. The expression of type I enzyme is positively correlated with age, serum PSA concentration, pathological stage and Gleason score. These findings suggest that these enzymes may play an important role in the development and progression of prostate cancer in the elderly population. Type I enzyme may have a certain significance in judging the biological behavior and prognosis of prostate cancer.

Key words: 5-α reductase, Gleason score, TNM stage, prostate specific antigen (PSA), prostate cancer

CLC Number:

R737.25

Sun Jian, Jin Song, Zhao Hongying, Liu Yang, Jin Mulan, Xing Nianzeng, Niu Yinong. Correlation between 5-α reductase and biological behavior of prostate cancer[J]. Journal of Capital Medical University, 2016, 37(3): 307-312.

References

[1] Wu Y, Godoy A, Azzouni F, et al. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5alpha-reductase inhibitors[J]. Prostate, 2013, 73(13): 1470-1482.
[2] Wang K, Fan D D, Jin S, et al. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications[J]. Asian J Androl, 2014, 16(2): 274-279.
[3] NCCN. The NCCN prostate cancer clinical practice guidelines in oncology (version 2.2016)[EB/OL]. Fort Washington: NCCN,2016[2016-03-13]. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pd
[4] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[5] 樊东东,王凯,靳松,等. 5-α还原酶在人前列腺组织中的差异性表达及其抑制剂治疗前列腺疾病的临床应用[J]. 中华泌尿外科杂志,2015, 36(1): 75-78.
[6] Godoy A, Kawinski E, Li Y, et al. 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression[J]. Prostate, 2011, 71(10): 1033-1046.
[7] Thomas L N, Douglas R C, Lazier C B, et al. Type 1 and Type 2 5α-reductase expression in the development and progression of prostate cancer[J]. Eur Urol, 2008, 53(2): 244-252.
[8] Silver R I, Wiley E L, Davis D L, et al. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease[J]. J Urol, 1994, 152(2 Pt 1): 433-437.
[9] Das K, Lorena P D, Ng L K, et al.Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer[J]. Endocr Relat Cancer,2010, 17(3): 757-770.
[10] Ge R, Wang Z, Bechis S K, et al. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate[J]. Am J Pathol, 2015, 185(3): 870-882.
[11] Niu Y, Ge R, Hu L, et al. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy[J]. Prostate, 2011,71(12):1317-1324.
[12] Uysal F, Akkoyunlu G, Ozturk S. Dynamic expression of DNA methyltransferases (DNMTs) in oocytes and early embryos[J]. Biochimie, 2015, 116: 103-113.
[13] Titus M A, Gregory C W, Ford O H 3rd, et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer[J]. Clin Cancer Res, 2005, 11(12): 4365-4371.
[14] 秦桂萍,华玉兰,侯海娜. 前列腺癌组织p504S和p63与血清PSA表达水平相关性分析[J]. 中华肿瘤防治杂志, 2013,20(3):200-202.
[15] 杜雄,惠起源,尹香利,等. PSA、CgA及PCA3在前列腺癌中的表达及临床意义[J]. 解放军医药杂志,2014,26(2):47-49.
[16] 王炜,李传刚,刘辉,等. 前列腺特异性抗原对前列腺癌诊断价值的探讨[J]. 中国医科大学学报, 2016,45(1):61-65,69.
[17] Loeb S, Catalona W J. Prostate-specific antigen in clinical practice[J]. Cancer Lett, 2007, 249(1): 30-39.
[18] 刘贺亮,王禾,杨晓剑,等. 血清PSA、FPSAR与前列腺癌病理分级、临床分期的相关性研究[J]. 中华男科学, 2002,8(4): 261-263.